Strong Revenue and Bookings Growth
Certara reported first quarter revenue of $106 million, representing a 10% growth compared to Q1 2024. Bookings reached $118.2 million, a 12% increase from the previous year.
Significant Software Segment Performance
Software revenue for Q1 2025 was $46.4 million, an 18% increase from the prior year, with software bookings growing by 23%. Chemaxon contributed $5.9 million to software revenue.
FDA Announcement on Animal Testing Phase-Out
The FDA's announcement to phase out animal testing has led to significant interest in Certara's Non-Animal Navigator solution, which leverages AI and modeling to replace animal testing in drug development.
Launch of Simcyp Simulator Version 24
Certara announced the 24th version of its Simcyp Simulator, featuring new drug interaction libraries and enhanced modeling capabilities. Simcyp has supported over 120 FDA-approved novel drug applications.
Share Repurchase Program
Certara announced a $100 million share repurchase authorization, with approximately $25 million repurchased to date, reflecting confidence in the company's long-term growth strategies.
Adjusted EBITDA Growth
Adjusted EBITDA for Q1 2025 was $34.8 million, up from $29.1 million in Q1 2024, with a margin of 33%.